SOMAÍ Pharmaceuticals

Home
SOMAÍ Pharmaceuticals

Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

02/12/2025

A key difference between a medically certified oil vaporizer and a non-medically approved one lies in their regulatory standard. Non-medical units are often consumer-grade devices designed without stringent oversight of materials, manufacturing, or long-term product stability. In contrast, medically certified vaporizers must meet the same rigorous requirements as other pharmaceutical equipment. This includes using medical-grade materials, meeting biological testing standards such as 10993 and 18562, and demonstrating that the device delivers a consistent dose of medicine over its entire lifespan. This provides a crucial level of assurance for doctors, pharmacists, and insurance companies that is absent with uncertified consumer devices.

Read the full article by Michael Sassano here: https://cannareporter.eu/en/2025/12/02/EU-certified-medical-vaporizers-are-entering-the-market--setting-a-new-regulatory-standard./

airobrands official

24/11/2025

We’re proud to announce the launch of Soma OG in the United Kingdom — SOMAÍ’s in-house flower brand.

Soma OG is synonymous with premium quality, featuring indoor-cultivated, non-irradiated, hand-trimmed flowers. Every step of the process is carefully controlled to ensure authenticity and excellence — from seed to the sophisticated packaging that reflects the essence of a truly “OG” product.

Each batch is grown in small, controlled environments, hand-selected by SOMAÍ’s global cultivation network, and verified under EU-GMP and GACP standards.

The launch of Soma OG expands SOMAÍ’s portfolio in the UK, strengthening our commitment to serving patients through regulated medical channels. Soma OG will be available across the country, ensuring broad and reliable patient access.

At SOMAÍ, we believe that consistency, value, and patient trust define true medical excellence. Soma OG embodies this philosophy — delivering carefully crafted flower designed to meet the highest pharmaceutical expectations while honoring the natural essence of the plant.

Learn more: www.somaipharma.eu
Contact: hello@somaipharma.eu

17/11/2025

Members of our Australian team recently visited Thailand, gaining firsthand insight into the exceptional care, precision and controlled indoor environments driving Thailand’s next generation of cannabis cultivation.

This visit served as a reminder that perceptions of Thai cannabis are evolving, and deservedly so. Behind the headlines and assumptions lies a growing pharmaceutical-grade ecosystem, one we are proud to integrate into our global supply network.

17/11/2025

Spain’s Royal Decree on Medicinal Cannabis is now official, a long-awaited and highly significant move that finally integrates cannabis-based medicines into the national healthcare system under strict pharmaceutical controls. This marks a definitive shift away from political debate and toward evidence-based medicine, where standardized extract formulations, clinical oversight, and patient safety take center stage.

This new regulatory framework in Spain signals a decisive move toward recognizing cannabis extracts as a legitimate therapeutic agent, managed with the same rigor as any other pharmaceutical product. The implementation of this decree is a major milestone, not just for Spanish patients but for the entire European Union, as it sets a highly credible standard for the future of cannabinoid therapeutics.

Read the latest news by Michael Sassano published in Krautinvest: https://krautinvest.de/spain-takes-a-major-step-toward-pharmaceutical-grade-cannabis-regulation-a-new-standard-for-europe/

12/11/2025

Cookies, the most globally recognized cannabis brand, is entering global medical markets with a full extract portfolio through a strategic partnership with SOMAÍ.

This collaboration marks a new era for full-branded portfolios of medicinal cannabis products with Cookies' signature terpene and flavonoid profiles — the foundation of its world-renowned flower reputation — are now refined, standardized, and transformed into pharmaceutical-grade extracts under SOMAÍ’s precise EU-GMP manufacturing standards.

“At SOMAÍ, we believe that taste isn’t just an experience — it’s a part of how patients connect with their medicine,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “Bringing Cookies’ iconic terpene blends into the medical space allows us to merge culture with compliance and deliver products that patients trust, enjoy, and truly benefit from.”

“SOMAÍ brings a level of pharmaceutical rigor and global ex*****on that is rare in this industry. Their ability to translate culture and cultivar nuance into standardized, medical-grade formulations is unmatched. We are proud to partner with a company that honors Cookies’ legacy while elevating it into regulated markets worldwide,” said Parker Berling, President, Cookies.

Read the full news: https://www.einpresswire.com/article/866319607/soma-adds-international-lifestyle-brand-cookies-to-global-medical-cannabis-markets

11/11/2025

🌿 Excellence starts in the grow room.

Precision, patience, and passion — that’s what defines SOMAÍ flower.

Together with our partners, we cultivate consistency, purity, and care.

Jack Herer Brands
Cookies
Sherbinskis
Iridescent .med
Cali Dior

💙

10/11/2025

Not all experiences are created equal.

At SOMAÍ, science unlocks the full spectrum of terpenes — delivering fruit-inspired flavors, reliable consistency, and a richer sensory journey.

Because taste isn’t just a detail, it’s an experience you remember.

👉 Learn more at www.somaipharma.eu

06/11/2025

The global cannabis industry has experienced both great success and significant challenges in 2025. Volumes are surging and new countries are coming online, signaling market expansion. However, a „dark cloud“ hangs over these numbers as regulators in key selling markets—such as the U.K., Germany, and Australia—and exporting countries like Portugal adjust to the increased volumes and seek greater control. A real tug-of-war has emerged, with successful legal cannabis strategies being met by attempts at new regulation to address the fast advancements in the sector. Cannabis entrepreneurs are facing sleepless nights trying to keep up with the changing landscape and the need to meet surging demand.

Read the latest article byMichael Sassano published in Krautinvest: https://krautinvest.de/global-cannabis-see-saw-surging-demand-meets-tightening-regulations/

05/11/2025

We’re proud to share that SOMAÍ’s Co-Founder, George Bellow, will speak at Talman Group’s upcoming event in London!

🎤 Panel: The Evolving Role of Cannabis in the Pharmaceutical Sector – How do cannabis therapeutics fit into the pharmaceutical industry?
📅 Date: November 10, 2025
🕛 Time: 12:00
📍 Location: London, UK
🔗 Event details: https://thetalmangroup.com/talman-events/talman-london-2025/

As medical cannabis becomes increasingly common in European pharmacies, this panel brings together industry experts to explore how pharmaceutical cannabis products are reshaping the landscape.

George will join fellow thought leaders to discuss:
- How the pharmaceutical cannabis sector differentiates itself within the wider European market;
- Key factors and opportunities for investors;
- The evolution of the pharmaceutical industry’s approach to cannabis as medicine.

SOMAÍ continues to drive this evolution as a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO), shaping the future of cannabinoid-based therapeutics worldwide.

03/11/2025

Join us in recognising Medical Cannabis Awareness Week 2025!

This week we raise our voices for patients, for progress, for better access to cannabinoid-based therapies.

At SOMAÍ, we believe in small-batch, indoor craft grows, personally selected by our team worldwide, offering compassionate pricing and unwavering care.

As the global distributor and manufacturer, we’re proud to support clinicians, researchers and patients on the journey to better health.

28/10/2025

airobrands official, a U.S. multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC, has received regulatory approval for its CE-marked Class IIa medical handheld liquid inhalation device, the Airo Medical Inhalation System, across Europe. This planned launch will introduce the second EU-certified device of its kind, designed specifically for the delivery of cannabinoid-based medicines under strict medical standards.

This milestone will mark the entry of a precision-engineered device into regulated medical markets, supported by a strategic partnership with SOMAÍ, which will manufacture EU-GMP inhalation oils and serve as the exclusive global distributor for the system’s cartridge line and API’s.

The Airo medical inhalation device is built in full compliance with EU Medical Device Regulation, offers a rechargeable, CE-certified platform engineered for precision, safety, and regulatory integrity. Its ergonomically rounded design ensures comfort and ease of use—critical factors for patients managing chronic therapies. This user-friendly form factor will not only support better patient adherence but will also allow for discreet, consistent dosing with confidence.

Learn more about the product: https://airobrands.com/international/

Read the full news here: https://www.einpresswire.com/article/862201259/airo-brands-announces-ce-certified-medical-inhalation-device-in-partnership-with-soma

22/10/2025

🔹 Inhalation as Medication: Fast, Precise, Effective

When it comes to cannabinoid-based treatment, inhalation offers unique therapeutic advantages.

🌀 Faster onset of action — effects can begin within minutes
🌀 Greater dose control — ideal for titration and managing breakthrough symptoms
🌀 Higher bioavailability — more of the active ingredients reach systemic circulation
🌀 Non-invasive administration — no need for swallowing or digestion

At SOMAÍ, we are committed to advancing inhalation formats that meet the highest pharmaceutical standards — combining patient-friendly delivery with clinical precision.

💡 From fast-acting relief to tailored treatment options, inhalation is helping redefine how cannabis-based medicines are prescribed — and experienced.

Address

Website

http://www.somaipharma.eu/

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Want your practice to be the top-listed Clinic?

Country:

City:

02/12/2025

24/11/2025

17/11/2025

17/11/2025

12/11/2025

11/11/2025

10/11/2025

06/11/2025

05/11/2025

03/11/2025

28/10/2025

22/10/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share